We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+66.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.82B
AUM Growth
-$64.9M
Cap. Flow
+$24.6M
Cap. Flow %
1.35%
Top 10 Hldgs %
65.19%
Holding
53
New
8
Increased
7
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$59.6M
2
JANX icon
Janux Therapeutics
JANX
+$55.5M
3
DRUG
Bright Minds Biosciences
DRUG
+$37.3M
4
OKUR
OnKure Therapeutics
OKUR
+$27.8M
5
BIOA
BioAge Labs
BIOA
+$17.2M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$93M
2
PCVX icon
Vaxcyte
PCVX
+$57.1M
3
BHVN icon
Biohaven
BHVN
+$16.2M
4
URGN icon
UroGen Pharma
URGN
+$15M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALMS
26
Alumis Inc
ALMS
$3.46B
$16.9M 0.93%
2,147,396
– –
OKUR
27
OnKure Therapeutics
OKUR
$167M
$15.8M 0.87%
+1,837,739
New +$27.8M
AVBP icon
28
ArriVent BioPharma
AVBP
$1.43B
$15.6M 0.86%
585,462
– –
ABVX
29
Abivax
ABVX
$11.5B
$15.6M 0.86%
2,130,000
– –
ENGN icon
30
enGene Therapeutics
ENGN
$121M
$15.5M 0.85%
2,323,595
+1,323,595
+132% +$10.3M
BIOA
31
BioAge Labs
BIOA
$539M
$15.2M 0.84%
2,629,529
+1,000,000
+61% +$17.2M
BMEA icon
32
Biomea Fusion
BMEA
$90.6M
$13.9M 0.76%
3,570,872
– –
MBX
33
MBX Biosciences
MBX
$3.14B
$12.9M 0.71%
700,000
– –
SEPN
34
Septerna Inc
SEPN
$1.73B
$12.8M 0.7%
+560,000
New +$13.2M
IBRX icon
35
ImmunityBio
IBRX
$7.99B
$7.68M 0.42%
+3,000,000
New +$12.5M
ELVN icon
36
Enliven Therapeutics
ELVN
$4.42B
$5.63M 0.31%
+250,000
New +$6.48M
SPRY icon
37
ARS Pharmaceuticals
SPRY
$603M
$5.28M 0.29%
+500,000
New +$7M
YARW
38
Yarrow Bioscience, Inc. Common Stock
YARW
$115M
$4.67M 0.26%
27,887
– –
KALA icon
39
KALA BIO
KALA
$14.4M
$4.19M 0.23%
+12,061
New +$3.8M
GHRS icon
40
GH Research
GHRS
$2.06B
$4.15M 0.23%
593,043
– –
YMAB
41
DELISTED
Y-mAbs Therapeutics
YMAB
$3.33M 0.18%
425,000
-1,025,000
-71% -$12.5M
URGN icon
42
UroGen Pharma
URGN
$2.3B
$3.19M 0.18%
300,000
-1,250,000
-81% -$15M
OMER icon
43
Omeros
OMER
$952M
$2.96M 0.16%
+300,000
New +$2.06M
STOK icon
44
Stoke Therapeutics
STOK
$2.08B
$2.8M 0.15%
254,161
-173,002
-41% -$2.13M
BHVN icon
45
Biohaven
BHVN
$2.21B
$2.07M 0.11%
55,539
-346,424
-86% -$16.2M
VERV
46
DELISTED
Verve Therapeutics
VERV
$1.97M 0.11%
350,000
– –
ARTV
47
Artiva Biotherapeutics
ARTV
$553M
$1.04M 0.06%
103,633
– –
RAPT
48
DELISTED
RAPT Therapeutics
RAPT
$316K 0.02%
25,000
-37,094
-60% -$471K
ANAB icon
49
AnaptysBio
ANAB
$1.69B
– –
-342,465
Closed -$11.5M
KRRO icon
50
Korro Bio
KRRO
$192M
– –
-265,826
Closed -$8.88M
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Cormorant Asset Management held 53 positions worth $1.82B, down 3.4% from $1.89B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Cormorant Asset Management's Q4 2024 filing shows 8 new, 7 increased, 11 reduced and 5 closed positions. Its largest new stake was Bright Minds Biosciences: 1,059,331 shares worth $38.2M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $93M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Cormorant Asset Management's largest Q4 2024 buy was Bright Minds Biosciences: 1,059,331 shares worth $38.2M.
  • Cormorant Asset Management added most to Praxis Precision Medicines in Q4 2024, an estimated $59.6M increase.
  • Cormorant Asset Management's biggest Q4 2024 reduction was Vaxcyte, cutting an estimated $57.1M.
  • Cormorant Asset Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $93M.
  • Cormorant Asset Management's ten largest holdings make up 65% of its $1.82B portfolio in Q4 2024.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q4 2024.
  • Cormorant Asset Management's portfolio value fell 3.4% quarter-over-quarter to $1.82B.

Based on Cormorant Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.